The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Skin Trust Club - update

4 Jul 2022 07:00

RNS Number : 1166R
Deepverge PLC
04 July 2022
 

4 July 2022

 

DeepVerge PLC

 

("DeepVerge" or "the Company" or "the Group")

 

New consumer offering, Skin Trust Club, generates £1m plus sales

20 new skincare sales and marketing agreements in UK & US in Q2

 

DeepVerge plc (AIM: DVRG) is pleased to announce that its new consumer offering, Skin Trust Club, powered by Labskin, has generated more than £1m in sales and signed 20 new sales and marketing agreements ("Agreements")with new era skin care companies so far this year, opening up multiple routes to potential new revenues and market audiences across the UK and US.

 

These Agreements create three new potential sources of revenues:

1. Client product validation on Labskin before being available on Skin Trust Club marketplace;

2. Affiliate fee income for sale of client skincare companies products via Skin Trust Club and for Skin Trust Club sales via partner routes to market; and

3. Data for product development of new products.

The Agreements give Skin Trust Club access to a catalogue of more than 500 skincare products that are being tested and curated by Labskin scientists and Skin Trust formulators, to offer Skin Trust Club members recommendations of suitable skincare products for morning and evening skin care routines, based on their personalised skin reports.

As Skin Trust Club data grows, increasing by thousands of new microbiome samples each month, it creates a rich learning environment for the Company's machine learning and AI. This world-leading skin microbiome database enables the Company to offer digital test solutions on a range of skin diseases to existing corporate clients and to the industry in general, for faster, better and more cost effective product development, offering the potential for future revenues for the platform.

Gerard Brandon, CEO of DeepVerge plc, commented:

"Skin Trust Club has evolved rapidly from a science based skin test in a laboratory to a personalised skincare solution that offers a unique consumer experience. By learning direct from consumers, with insights from the largest and fastest growing skin microbiome database, we offer our partners new compelling services, that generate additional routes to markets and revenue generating opportunities. We are delivering personalised beauty service experience to the consumer on a platform that enhances the revenue streams of Labskin, Skin Trust Club and our skincare clients."

 

 

DeepVerge plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

 

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins; Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin

 

Skin Trust Club

Skin Trust Club incorporates an artificial intelligence Skincare App and Home Test Kit that provide simple, at-home skin microbiome testing for personalised skincare and skin health tracking. The self-administered skin swab is a remote trial and allows the participant to conduct each stage of the trial without interaction. Skin Trust Club's DNA Test generates a report that consumers can use to manage their custom skincare regime. Analysis of skin attributes provides information to create hundreds of different product combinations to suit a person's unique skin microbiome.

 

Labskin (Life Science Division)

Labskin is a 3D human skin equivalent test platform that scientifically proves the impact of skincare product claims in healthcare, life sciences, skin microbiome clinical trials, pharmaceutical and cosmetics industries. Labskin have been pioneering the development of a laboratory grown human skin platform for 15 years and is the only commercially available lab-grown full thickness human skin model that naturally mimic the skins' microbiome. Labskin's virtual clinical trials with remote collection of human volunteers' skin microbiome provides a solution for the collection of volunteer microbiomes to allow for lab-controlled trials of advanced skin models and human microbiomes. As the data bank of remote volunteers grow, the higher the accuracy and increased reliability of virtual product testing that can be provided to clients, eliminating early human trial and error testing and resulting in a faster time to market. The Labskin test platform and protocols help clients maintain an optimum real-world environment, when testing their new ingredients and existing products, that shows the positive or negative impact on skin's natural microflora.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFZGGNRZNGZZG
Date   Source Headline
1st Feb 20218:30 amRNSAppointment of former IBM Legal Counsel as CoSec
1st Feb 20217:00 amRNSAppointment of former IBM Legal Counsel as CoSec
25th Jan 20212:22 pmRNSExercise of Warrants and Total Voting Rights
18th Jan 20214:51 pmRNSExercise of Options and Total Voting Rights
15th Jan 20217:00 amRNSCompletion of Compulsory Acquisition; TVR
11th Jan 20217:00 amRNSDVRG confirms maiden Q4 profit;guides £10m in 2021
11th Dec 20207:00 amRNSNew Labskin service - update
3rd Dec 20204:26 pmRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTrading Update & Investor Presentation
27th Nov 20207:00 amRNSInterim analysis from Aberdeen Uni - Labskin study
25th Nov 20207:00 amRNSInvestor presentation and corporate update
23rd Nov 20209:26 amRNSHolding(s) in Company
19th Nov 20205:25 pmRNSIssue of Share Options/PDMR Dealings
18th Nov 202012:17 pmRNSTR-1: Notification of major holdings
18th Nov 202011:06 amRNSSecond Price Monitoring Extn
18th Nov 202011:00 amRNSPrice Monitoring Extension
17th Nov 20203:43 pmRNSDirector/PDMR Shareholding
17th Nov 20203:38 pmRNSAllotment of Shares Following Close of Offer
16th Nov 20207:00 amRNSUpdate on detection products
13th Nov 20205:22 pmRNSHolding(s) in Company
10th Nov 20202:57 pmRNSExercise of Warrants and Total Voting Rights
10th Nov 20201:14 pmRNSExchange and Grant of Options and Warrants
10th Nov 20207:00 amRNSAppointment of Non-Executive Director
9th Nov 20205:30 pmRNSDeepverge
9th Nov 20205:02 pmRNSAllotment of Shares and Level of Acceptances
9th Nov 20202:05 pmRNSSecond Price Monitoring Extn
9th Nov 20202:00 pmRNSPrice Monitoring Extension
9th Nov 20208:46 amRNSHolding(s) in Company
9th Nov 20208:06 amRNSOffer Unconditional in all respects
3rd Nov 20203:00 pmRNSOFFER UNCONDITIONAL AS TO ACCEPTANCES; EXTENDED
26th Oct 20206:31 pmRNSForm 8.3 - Deepverge PLC
23rd Oct 20204:41 pmRNSSecond Price Monitoring Extn
23rd Oct 20204:35 pmRNSPrice Monitoring Extension
23rd Oct 20204:08 pmRNSComment on detection of COVID-19 in UK Sewage
22nd Oct 20204:40 pmRNSSecond Price Monitoring Extn
22nd Oct 20204:35 pmRNSPrice Monitoring Extension
22nd Oct 20209:05 amRNSSecond Price Monitoring Extn
22nd Oct 20209:00 amRNSPrice Monitoring Extension
13th Oct 20203:55 pmRNSPublication of Offer Document; Rule 15 letters
13th Oct 20203:45 pmRNSReplacement - Form 8 (OPD) - Modern Water plc
9th Oct 20207:00 amRNSUpdate on Offer for Modern Water plc by DeepVerge
7th Oct 20204:40 pmRNSSecond Price Monitoring Extn
7th Oct 20204:35 pmRNSPrice Monitoring Extension
7th Oct 20202:05 pmRNSSecond Price Monitoring Extn
7th Oct 20202:00 pmRNSPrice Monitoring Extension
7th Oct 202011:05 amRNSSecond Price Monitoring Extn
7th Oct 202011:00 amRNSPrice Monitoring Extension
7th Oct 20209:05 amRNSSecond Price Monitoring Extn
7th Oct 20209:00 amRNSPrice Monitoring Extension
6th Oct 20205:21 pmRNSForm 8.3 -Deepverge PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.